drugset / Trial / NCT05858983
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of subretinal administration of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2025-11-30
- Completion
- 2029-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT-001 | Unknown | — | Other |